Publications by authors named "Gavin Blyth"

Claim this Profile
D
Development of a SIN1 targeting inhibitor as a novel therapeutic approach for the treatment of malignancies.
Elspeth M Beauchamp, Atul Jain, Matt Clutter, Dominik Nahotko, Emely Lopez Fajardo, Gavin T Blyth

Mol Cancer Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Potent and Selective MNK Kinase Inhibitors for the Treatment of Leukemia.
Purav P Vagadia, Javier Izquierdo-Ferrer, Candice Mazewski, Gavin Blyth, Elspeth M Beauchamp

J Med Chem· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms.
Diana Saleiro, Jeremy Q Wen, Ewa M Kosciuczuk, Frank Eckerdt, Elspeth M Beauchamp, Gavin T Blyth

Nat Commun· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
Hiroaki Katagi, Nozomu Takata, Yuki Aoi, Yongzhan Zhang, Emily J Rendleman, Gavin T Blyth

Neuro Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma.
Mariafausta Fischietti, Frank Eckerdt, Gavin T Blyth, Ahmet D Arslan, William M Mati

Oncogene· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitory effects of Tomivosertib in acute myeloid leukemia.
Milagros Suarez, Gavin T Blyth, Alain A Mina, Ewa M Kosciuczuk, Blazej Dolniak

Oncotarget· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitory effects of SEL201 in acute myeloid leukemia.
Ewa M Kosciuczuk, Aroop K Kar, Gavin T Blyth, Mariafausta Fischietti, Sameem Abedin

Oncotarget· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening.
Rama K Mishra, Matthew R Clutter, Gavin T Blyth, Ewa M Kosciuczuk, Amy Z Blackburn

Chem Biol Drug Des· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma.
Frank Eckerdt, Jessica Clymer, Jonathan B Bell, Elspeth M Beauchamp, Gavin T Blyth

Sci Rep· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent Antineoplastic Effects of Combined PI3Kα-MNK Inhibition in Medulloblastoma.
Frank Eckerdt, Jonathan B Bell, Elspeth M Beauchamp, Jessica Clymer, Gavin T Blyth

Mol Cancer Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.
Elspeth M Beauchamp, Sameem M Abedin, Sara G Radecki, Mariafausta Fischietti, Ahmet Dirim Arslan, Gavin T Blyth

Blood· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer.
Daphne Brisard, Frank Eckerdt, Lindsey A Marsh, Gavin T Blyth, Sarika Jain

Oncotarget· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IFN-γ-inducible antiviral responses require ULK1-mediated activation of MLK3 and ERK5.
Diana Saleiro, Gavin T Blyth, Ewa M Kosciuczuk, Patrick A Ozark, Beata Majchrzak-Kita

Sci Signal· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central Regulatory Role for SIN1 in Interferon γ (IFNγ) Signaling and Generation of Biological Responses.
Barbara Kroczynska, Gavin T Blyth, Robert L Rafidi, Beata Majchrzak-Kita, Lucy Xu

J Biol Chem· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo.
Ewa M Kosciuczuk, Diana Saleiro, Barbara Kroczynska, Elspeth M Beauchamp, Frank Eckerdt, Gavin T Blyth

Blood· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon γ (IFNγ) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses.
Barbara Kroczynska, Robert L Rafidi, Beata Majchrzak-Kita, Ewa M Kosciuczuk, Gavin T Blyth

J Biol Chem· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias.
Dany A Curi, Elspeth M Beauchamp, Gavin T Blyth, Ahmet Dirim Arslan, Nicholas J Donato

Oncotarget· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase.
Marco Colamonici, Gavin Blyth, Diana Saleiro, Amy Szilard, Meghan Bliss-Moreau

Oncotarget· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis